EGFR and colorectal cancer: In fact, vemurafenib, dabrafenib, or encorafenib do render benefits to colorectal cancer patients, however their use needs to be supplemented by simultaneous administration of anti-EGFR antibodies to avoid feedback activation of the EGFR [71].